2366-P: Evaluation of Sarcopenia in Adults over 50 Years with Type 1 Diabetes: Single-Centre Observational Study

Introduction and Objective: Sarcopenia is a progressive muscular disease described as a possible diabetes complication. Few evidence is available about prevalence of sarcopenia in people with type 1 diabetes (T1DM), especially in younger subjects. Methods: In a cross-sectional study, we enrolled people with T1DM, aged ≥50 years old, with ≥5 years of diabetes duration. Muscle mass was assessed by appendicular skeletal muscle mass index (ASMI) by dual-energy X-ray absorptiometry (DEXA), strength was assessed by handgrip (HGS) using dynamometer, and muscle performance was assessed by 4 meters speed-gait test. Sarcopenia was diagnosed according to European Working Group on Sarcopenia in Older People 2 (EWGSOP2) guidelines. Results: We enrolled 73 participants, 37 (51%) women, mean age 62.1 (SD 7.53) years, median duration of diabetes 36 [IQR 25-48] years, mean BMI 24.7 (3.2) Kg/m2, HbA1c 7.1 (0.9)%, 25 (34%) on MDI, 64% practicing moderate/high physical activity. 50 (68%) were <65 years (mean age 57.9 [4.5] years) and 23 (31%) were ≥65 years (70.9 [4.7] years). 7 (10%) subjects (n=71) presented lower muscle mass at DEXA compatible with sarcopenia; 4 subjects (6%) had ASMI below 5th percentile age-matched controls. ASMI was similar between older and younger subjects (≥65 years 7.03 (0.93) vs <65 years 7.08 (1.03), p=0.83) and it was correlated with BMI (rho=0.63, p<0.05). Over 52 participants, 9 subjects (17%) presented HGS compatible with sarcopenia, with no difference between older and younger (p=0.40). None of participants presented a gait-speed test compatible with sarcopenia. 2 (4%) participants presented an overt diagnosis of sarcopenia. ASMI and HGS were not associated with diabetes duration nor presence of microvascular complications. Conclusion: In high physically active younger people with T1DM, 10% of people had lower muscle mass and 17% presented muscle strength loss. The presence of muscle loss and strength were not associated with DMCs nor disease duration. Further data are required to understand predictive factors influencing muscle mass in T1DM. Disclosure L. Lucaccini Paoli: None. D. D'Amore: None. A. Rizzi: None. L. Tartaglione: None. F. Mammarella: None. A. Barberio: None. G. Sciaraffia: None. D. Pitocco: None.